ANIK logo

ANIK
Anika Therapeutics Inc.

636
Mkt Cap
$198.33M
Volume
98,848.00
52W High
$15.40
52W Low
$7.87
PE Ratio
-19.50
ANIK Fundamentals
Price
$14.80
Prev Close
$14.98
Open
$14.90
50D MA
$12.28
Beta
0.85
Avg. Volume
136,383.81
EPS (Annual)
-$0.7588
P/B
1.43
Rev/Employee
$480,080.85
$106.56
Loading...
Loading...
News
all
press releases
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200 Day Moving Average - What's Next?
Anika Therapeutics (NASDAQ:ANIK) Stock Passes Above 200 Day Moving Average - What's Next...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Share Price Crosses Above 200-Day Moving Average - Time to Sell?
Anika Therapeutics (NASDAQ:ANIK) Share Price Crosses Above 200-Day Moving Average - Here's Why...
MarketBeat·10d ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Shares Pass Above 200-Day Moving Average - What's Next?
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200-Day Moving Average - Here's What Happened...
MarketBeat·18d ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen raised Anika Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday...
MarketBeat·28d ago
News Placeholder
Trigran Investments Inc. Sells 415,296 Shares of Anika Therapeutics Inc. $ANIK
Trigran Investments Inc. lowered its stake in shares of Anika Therapeutics Inc. (NASDAQ:ANIK - Free Report) by 20.4% in the third quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·29d ago
News Placeholder
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference
Anika Therapeutics (NASDAQ:ANIK) CEO Steve Griffin outlined the company's strategy, product portfolio, and growth priorities during a presentation at the Canaccord Genuity Musculoskeletal Conference...
MarketBeat·1mo ago
News Placeholder
Anika Therapeutics (NASDAQ:ANIK) Announces Quarterly Earnings Results
Anika Therapeutics (NASDAQ:ANIK - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported $0.31 earnings per share for the quarter, beating analysts...
MarketBeat·1mo ago
News Placeholder
Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock
Barrington Research boosted their target price on Anika Therapeutics from $16.00 to $17.00 and gave the company an "outperform" rating in a research note on Friday...
MarketBeat·1mo ago
News Placeholder
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika (ANIK) delivered earnings and revenue surprises of +1,450.00% and +6.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Anika Therapeutics Q4 Earnings Call Highlights
Anika Therapeutics (NASDAQ:ANIK) detailed its fourth-quarter and full-year 2025 results and outlined its strategy for 2026 during its earnings call on Thursday, highlighting commercial-channel...
MarketBeat·1mo ago
<
1
2
...
>

Latest ANIK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.